A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer.

被引：0
|
作者：
Fernando, N [1 ]
Yu, D [1 ]
Morse, M [1 ]
Blobe, G [1 ]
Odogwu, L [1 ]
Crews, J [1 ]
Polito, A [1 ]
Honeycutt, W [1 ]
Franklin, A [1 ]
Hurwitz, H [1 ]
机构：
[1] Duke Univ, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：260S / 260S
页数：1
相关论文
共 50 条
  • [1] A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer
    Hurwitz, H
    Fernando, N
    Yu, DH
    Morse, M
    Blobe, G
    Gockerman, J
    Odogwu, L
    Mahon, M
    Truax, R
    Franklin, A
    ANNALS OF ONCOLOGY, 2005, 16 : 285 - 285
  • [2] A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer.
    Bendell, J. C.
    Fernando, N.
    Morse, M.
    Blobe, G.
    Yu, D.
    Sutton, L.
    Schaffer, S.
    Honeycutt, W.
    Franklin, A.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 156S - 156S
  • [3] A Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal Cancer
    Wong, Nan Soon
    Fernando, Nishan H.
    Nixon, Andrew B.
    Cushman, Stephanie
    Aklilu, Mebea
    Bendell, Johanna C.
    Morse, Michael A.
    Blobe, Gerard C.
    Ashton, Jill
    Pang, Herbert
    Hurwitz, Herbert I.
    ANTICANCER RESEARCH, 2011, 31 (01) : 255 - 261
  • [4] A phase ii study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer
    Bendell, J.
    Fernando, N.
    Morse, M.
    Blobe, G.
    Yu, D.
    Sutton, L.
    Vaccaro, G.
    Honeycutt, W.
    Franklin, A.
    Hurwitz, H.
    ANNALS OF ONCOLOGY, 2006, 17 : 67 - 67
  • [5] Capecitabine and oxaliplatin (XELOX) in combination with bevacizumab in the treatment of metastatic colorectal cancer: results of a phase II trial
    Bendell, J.
    Yu, D.
    Hurwitz, H.
    Morse, M.
    Blobe, G.
    Gockerman, J.
    Odogwu, L.
    Mahon, M.
    Truax, R.
    Fernando, N.
    EJC SUPPLEMENTS, 2005, 3 (02): : 189 - 189
  • [6] A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer.
    Overman, Michael J.
    Eng, Cathy
    Kee, Bryan K.
    Fogelman, David R.
    Fark, Christine
    Hippert, Rick
    Holter, Scott
    Issa, Jean-Pierre
    Hamilton, Stanley R.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [7] A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
    Uronis, Hope E.
    Bendell, Johanna C.
    Altomare, Ivy
    Blobe, Gerard C.
    Hsu, S. David
    Morse, Michael A.
    Pang, Herbert
    Zafar, S. Yousuf
    Conkling, Paul
    Favaro, Justin
    Arrowood, Christy C.
    Cushman, Stephanie M.
    Meadows, Kellen L.
    Brady, John C.
    Nixon, Andrew B.
    Hurwitz, Herbert I.
    ONCOLOGIST, 2013, 18 (03): : 271 - 272
  • [8] A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study
    Efrat Dotan
    Neal J. Meropol
    Barbara Burtness
    Crystal S. Denlinger
    James Lee
    David Mintzer
    Fang Zhu
    Karen Ruth
    Holly Tuttle
    Judi Sylvester
    Steven J. Cohen
    Journal of Gastrointestinal Cancer, 2012, 43 (4) : 562 - 569
  • [9] A Phase II Study of Oxaliplatin, Dose-intense Capecitabine, and High-dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer
    Wong, Nan Soon
    Fernando, Nishan H.
    Bendell, Johanna C.
    Morse, Michael A.
    Blobe, Gerard C.
    Honeycutt, Wanda
    Pang, Herbert
    Hurwitz, Herbert I.
    CLINICAL COLORECTAL CANCER, 2011, 10 (03) : 210 - 216
  • [10] Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
    Bazarbashi, Shouki
    Aljubran, Ali
    Alzahrani, Ahmad
    Mohieldin, Ahmed
    Soudy, Hussein
    Shoukri, Mohammed
    CANCER MEDICINE, 2015, 4 (10): : 1505 - 1513
12345